Literature DB >> 26399721

The role for surgery in high-risk prostate cancer.

Cécilia Lanchon1, Shahrokh F Shariat2, Morgan Rouprêt3,4.   

Abstract

High-risk prostate cancer (PCa) refers to a very heterogeneous subgroup of disease. Recent series have shown very promising results of radical prostatectomy (RP)-alone or part as a multimodality approach-in patients with high-risk PCa, with satisfactory survival curves even though biochemical recurrence rate was high. Adjuvant treatment (radiotherapy (RT) alone or combined with androgen deprivation) was necessary in 20 to 54 % of patients, notably in cases with positive surgical margins. As for functional outcomes, urinary continence was preserved in about 92 % of cases and overall potency in 60 %. When comparing RP versus RT as primary treatment for high-risk PCa, a recent meta-analysis found surgery to be associated with an improved cancer-specific mortality compared with RT. In selected high-risk PCa young patients, surgery appears to be a valid option. Patients should however be informed of the possibility of adjuvant treatment, as part of a multimodal approach.

Entities:  

Keywords:  High-risk Prostate cancer; Prognosis; Prostate cancer; Radical prostatectomy; Radiotherapy

Mesh:

Year:  2015        PMID: 26399721     DOI: 10.1007/s10354-015-0389-y

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  28 in total

1.  Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience.

Authors:  Chao-Yu Hsu; Steven Joniau; Raymond Oyen; Tania Roskams; Hein Van Poppel
Journal:  Eur Urol       Date:  2006-06-09       Impact factor: 20.096

2.  Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.

Authors:  A V D'Amico; A Desjardin; A Chung; M H Chen; D Schultz; R Whittington; S B Malkowicz; A Wein; J E Tomaszewski; A A Renshaw; K Loughlin; J P Richie
Journal:  Cancer       Date:  1998-05-15       Impact factor: 6.860

3.  Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.

Authors:  Martin Spahn; Steven Joniau; Paolo Gontero; Steffen Fieuws; Giansilvio Marchioro; Bertrand Tombal; Burkhard Kneitz; Chao-Yu Hsu; Katie Van Der Eeckt; Pia Bader; Detlef Frohneberg; Alessandro Tizzani; Hein Van Poppel
Journal:  Eur Urol       Date:  2010-03-17       Impact factor: 20.096

4.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

5.  Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes.

Authors:  Luigi Mearini; Elisabetta Nunzi; Vittorio Bini; Luca Lepri; Raffaella Bruno; Massimo Porena
Journal:  Urologia       Date:  2013-11-29

6.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

7.  Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Authors:  Stephen A Boorjian; R Jeffrey Karnes; Rosalia Viterbo; Laureano J Rangel; Eric J Bergstralh; Eric M Horwitz; Michael L Blute; Mark K Buyyounouski
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

8.  Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer.

Authors:  Stacy Loeb; Norm D Smith; Kimberly A Roehl; William J Catalona
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

9.  Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

Authors:  Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2007-10-12       Impact factor: 20.096

10.  Long-term outcome following radical prostatectomy for Gleason 8-10 prostatic adenocarcinoma.

Authors:  Naveen Pokala; Jerry J Trulson; Majdee Islam
Journal:  World J Urol       Date:  2014-02-09       Impact factor: 4.226

View more
  2 in total

1.  Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.

Authors:  I Henríquez; A Rodríguez-Antolín; J Cassinello; C Gonzalez San Segundo; M Unda; E Gallardo; J López-Torrecilla; A Juarez; J Arranz
Journal:  Clin Transl Oncol       Date:  2017-08-07       Impact factor: 3.405

2.  High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy.

Authors:  Chunhui Hu; Beibei Chen; Yibin Zhou; Yuxi Shan
Journal:  Cancer Cell Int       Date:  2017-04-11       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.